HTA ID Drug Brand Indication Assessment status Date
- Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumerate) Stribild® For the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®. Rapid review complete 20th May 2013
- Empagliflozin Jardiance® Add-on combination therapy: In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. Rapid review complete 17th June 2014
21030 Empagliflozin Jardiance® For the treatment of symptomatic chronic heart failure with reduced ejection fraction. NCPE Assessment Process Complete 28th April 2022
22068 Empagliflozin Jardiance® For the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40% Rapid review complete 20th October 2023
- Emtricitabine / tenofovir disoproxil fumarate Truvada® In combination with safer sex practices for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. Awaiting Applicant submission 18th July 2017
- Emtricitabine/tenofovir alafenamide Descovy® In combination with other antiretroviral agents (ARVs) for the treatment of adults and adolescents (≥12 years; body weight ≥35 kg) infected with human immunodeficiency virus (HIV) type 1 Rapid review complete 26th April 2016
- Emtricitabine/tenofovir disoproxil TEVA® For pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk Rapid review complete 22nd December 2017
24011 Enalapril maleate Aqumeldi® For the treatment of heart failure in children and adolescents from birth to less than 18 years of age. Rapid Review complete 12th April 2024
20037 Encorafenib Braftovi® In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy Assessment process complete 28th January 2022
- Encorafenib, binimetinib Braftovi®, Mektovi® For the treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation. Rapid review complete 23rd January 2019
22024 Enfortumab vedotin Padcev® As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor NCPE Assessment Process Complete 14th March 2024
21038 Entrectinib Rozlytrek® As monotherapy for the treatment of patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors Rapid review complete 28th September 2021
22055 Entrectinib Rozlytrek® As monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor and who have no satisfactory treatment options Rapid review complete 29th September 2022
- Enzalutamide Xtandi® First line treatment of adult men with mCRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated Assessment process complete 22nd June 2015
21022 Enzalutamide Xtandi® For the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy. Rapid review complete 7th July 2021
18056 Enzalutamide Xtandi® For the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). Assessment process complete 24th May 2022
- Enzalutamide Xtandi® For the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy. Assessment process complete 10th April 2014
24010 Epcoritamab Tepkinly® Epcoritamab (Tepkinly®) is indicated as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Rapid Review Complete 15th April 2024
- Epoprostenol Veletri® For the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH associated with connective tissue diseases) in patients with WHO FC III–IV symptoms to improve exercise capacity Rapid review complete 7th February 2017
22052 Eptinezumab Vyepti® For the prophylaxis of migraine in adults who have at least four migraine days per month Rapid review complete 20th October 2023
- Erenumab Aimovig® For the treatment of chronic and episodic migraine in adults who have at least 4 migraine days per month when initiating treatment with erenumab. Assessment process complete 30th September 2019
- Eribulin Halaven® For the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. Assessment process complete 7th December 2012
- Ertugliflozin Steglatro® For the treatment of the treatment 2 diabetes mellitus (T2DM) in individuals 18 years and over to improve glycaemic control. Rapid review complete 21st May 2018
19055 Esketamine Spravato® In combination with a SSRI or SNRI is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current depressive episode Assessment process complete 9th March 2021
- Eslicarbazepine Zebinix® For the treatment of Epilepsy Rapid review complete 1st September 2009
20013 Estradiol Oestrogel® Pump Gel For: Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women; Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. Rapid review complete 9th April 2020
22071 Estriol Blissel® Estriol (Blissel®) 50 micrograms per gram is indicated for local treatment of vaginal dryness in post- menopausal women with vaginal atrophy. Rapid Review Complete 23rd January 2023
- Etanercept Benepali® A biosimilar of the TNF-α inhibitor Etanercept (Enbrel®) for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, axial spondylitis and plaque psoriasis. Rapid review complete 30th May 2016
- Etelcalcitide Parsabiv® For the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis. Rapid review complete 1st September 2017
- Everolimus Afinitor® Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor Rapid review complete 15th October 2012
- Everolimus Votubia® For the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC. Rapid review complete 26th April 2017
- Everolimus Votubia® For the treatment of patients aged 3 years and older with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery Rapid review complete 14th October 2011
- Evolocumab Repatha® For both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia. Assessment process complete 16th May 2018
- Exenatide Bydureon® For the treatment of type II diabetes mellitus combined with Metformin, Sulphonylurea, Thiazolidinedione, Metform and SU and Metformn and TZD in adults who have not acheived glycaemic control on maximally tolerated doses of these oral therapies. Rapid review complete 9th June 2011
- Fampridine Fampyra® For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7). Assessment process complete 17th August 2012
22060 Faricimab Vabysmo ® For the treatment of adult patients with neovascular (wet) age-related macular degeneration. Awaiting full HTA submission from Applicant 3rd October 2023
22061 Faricimab Vabysmo ® For the treatment of adult patients with visual impairment due to diabetic macular oedema (DMO). Awaiting full HTA submission from Applicant 3rd October 2023
21069 Fedratinib Inrebic® For the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis who are JAK inhibitor–naive or have been treated with ruxolitinib.   Rapid Review Complete 20th January 2022
23048 Fenfluramine (Fintepla®) Fintepla® Fenfluramine (Fintepla®) is indicated for seizures associated with Dravet Syndrome (as an add-on therapy for patients two years of age and older). Awaiting full HTA submission from Applicant 7th November 2023
23051 Fenfluramine Fintepla® Fenfluramine (Fintepla®) is indicated for patients (two years of age and older) with Lennox-Gastaut Syndrome as an add-on therapy to other anti-epileptic medicines. Awaiting full HTA submission from Applicant 7th November 2023
- Ferric maltol Feraccru® For the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients. Assessment process complete 6th September 2016
- Ferumoxytol Rienso® For the treatment of iron deficiency anaemia in adult patients with chronic kidney disease (CKD).  Assessment process complete 17th August 2012
24005 Fezolinetant Veoza™ Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. Pre submission consultation scheduled 10th April 2024
- Fidaxomicin Dificlir® For the treatment of CDI also known as CDAD in adult patients. Rapid Review Assessment process complete 5th February 2013
20047 Filgotinib Jyseleca® As monotherapy or in combination with methotrexate for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs. Rapid Review Complete 16th November 2020
21048 Filgotinib Jyseleca® For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Assessment process complete 10th December 2021
22012 Finerenone Kerendia® For the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. NCPE Assessment Process Complete 22nd August 2023
23077 Finerenone Kerendia® Finerenone (Kerendia®) is indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes (T2D) in adults. Rapid Review Complete 23rd January 2024
- Fingolimod Gilenya® For the treatment of highly active relapsing-remitting multiple sclerosis. Full Assessment Complete 22nd September 2011
- Fluocinolone acetonide intravitreal implant Iluvien® For the treatment of vision impairment associated with chronic diabetic macular oedema (DMO) considered insufficiently responsive to available therapies. Rapid Review Complete 1st March 2016